年龄对急性冠脉综合征患者 guided de-escalation 抗血小板治疗结局的影响:TROPICAL-ACS 随机试验分析
TROPICAL-ACS 预设分析按年龄评估 guided de-escalation 抗血小板策略对急性冠脉综合征 PCI 患者临床结局的影响。年轻患者(≤70 岁)主要终点事件率显著低于标准治疗组,老年患者(>70 岁)两组无显著差异。年龄越小,相对风险降低越明显,主要归因于出血事件减少。
要点
- 年龄≤70 岁患者 guided de-escalation 较标准治疗主要终点事件率显著降低。
- 年龄>70 岁患者两组主要终点事件率无显著差异,但事件绝对风险更高。
- 年龄与治疗效应存在交互,年龄越小相对风险降低越明显。
核心结论
- guided de-escalation 的治疗效应取决于患者年龄,年轻患者获得显著净临床获益。
研究设计与样本
- TROPICAL-ACS 随机试验的预设分析,患者按 1:1 随机分配至标准治疗组或 guided de-escalation 组。
主要发现
- 年轻患者(≤70 岁,n=2240)1 年主要终点事件率 guided de-escalation 组 5.9% vs 对照组 8.3%,HR 0.70(95%CI 0.51-0.96),P=0.03,NNT=42。
- 老年患者(>70 岁,n=370)1 年主要终点事件率 guided de-escalation 组 15.5% vs 对照组 13.6%,HR 1.17(95%CI 0.69-2.01),P=0.56。
- 以年龄为连续变量分析,主要终点相对风险降低随年龄降低而增加(Pint=0.02),归因于出血事件显著减少。
关键数值与推荐
- 主要终点定义为心血管死亡、心肌梗死、卒中或 BARC 标准≥2 级出血。
- guided de-escalation 方案:1 周普拉格雷后 1 周氯吡格雷,出院后第 14 天起基于血小板功能检测指导维持治疗(氯吡格雷或普拉格雷)。
- 标准治疗组:普拉格雷治疗 12 个月。
临床怎么用
- 对年龄≤70 岁的急性冠脉综合征 PCI 患者,可考虑 guided de-escalation 抗血小板策略以降低净临床事件。
- 对年龄>70 岁患者,guided de-escalation 的安全性和有效性与统一普拉格雷治疗相似,但因样本量有限需进一步研究。
局限性
- 老年患者亚组样本量有限,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Guided de-escalation of P2Y12-inhibitor treatment was recently identified as an effective alternative treatment strategy in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention. Safety and efficacy of this strategy may differ in relation to patient's age. This pre-specified analysis of the TROPICAL-ACS trial aimed to assess the impact of age on clinical outcomes following guided de-escalation of antiplatelet treatment in ACS patients. METHODS AND RESULTS: Patients were randomly assigned in a 1:1 fashion to either standard treatment with prasugrel for 12 months (control group) or to a guided de-escalation regimen (1 week prasugrel followed by 1 week clopidogrel and platelet function testing guided maintenance therapy with clopidogrel or prasugrel from day 14 after hospital discharge; guided de-escalation group). We used Cox regression models to assess the associations of age on clinical endpoints and interactions. In younger patients (age ≤70, n = 2240), the 1 year incidence of the primary endpoint (cardiovascular death, myocardial infarction, stroke, or bleeding ≥ grade 2 according to Bleeding Academic Research Consortium criteria) was significantly lower in guided de-escalation vs. control group [5.9% vs. 8.3%; hazard ratio (HR) 0.70, 95% confidence interval (CI) 0.51-0.96; P = 0.03, number needed to treat = 42]. In elderly patients (age >70, n = 370), the absolute risk of events was higher without significant differences between guided de-escalation vs. control group (15.5% vs. 13.6%; HR 1.17, 95% CI 0.69-2.01; P = 0.56). When the impact of age, as a continuous variable, was analysed on outcomes after guided de-escalation vs. control treatment, an increasing relative risk reduction was observed in the primary endpoint by decreasing age (Pint = 0.02), due to significant reductions in bleeding. CONCLUSION: Treatment effects of guided de-escalation for P2Y12 inhibitors depend on patient's age with younger patients deriving a significant net clinical benefit. Although the safety and efficacy of guided de-escalation in the elderly was similar to uniform prasugrel therapy, this should be further investigated due to the limited sample size of this group.
引用
- Sibbing D, Gross L, Trenk D, et al. Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial. Eur Heart J. 2018. PMID: 29912422. doi:10.1093/eurheartj/ehy332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。